Kurs
+4,35%
Kurs
+4,35%
Open
6,70
High
7,20
Low
6,70
Close
7,20
Kursutveckling under dagen för detta pressmeddelande
(DKK).
Kalender
| Est. tid* | ||
| 2026-01-10 | N/A | Årsstämma |
| 2025-11-30 | N/A | Bokslutskommuniké 2025 |
| 2025-07-17 | 08:30 | Kvartalsrapport 2025-Q3 |
| 2025-04-17 | 08:30 | Kvartalsrapport 2025-Q2 |
| 2025-02-19 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-03 | - | X-dag ordinarie utdelning CSMED 0.00 DKK |
| 2025-01-31 | - | Årsstämma |
| 2025-01-09 | - | 15-6 2025 |
| 2024-11-30 | - | Bokslutskommuniké 2024 |
| 2024-11-12 | - | Extra Bolagsstämma 2024 |
| 2024-08-15 | - | Kvartalsrapport 2024-Q3 |
| 2024-05-30 | - | Årsstämma |
| 2024-05-17 | - | Kvartalsrapport 2024-Q2 |
| 2024-03-01 | - | X-dag ordinarie utdelning CSMED 0.00 DKK |
| 2024-02-14 | - | Bokslutskommuniké 2023 |
| 2024-02-14 | - | Kvartalsrapport 2024-Q1 |
| 2023-12-15 | - | X-dag ordinarie utdelning CSMED 0.00 DKK |
| 2023-07-18 | - | Kvartalsrapport 2023-Q3 |
| 2023-05-17 | - | Kvartalsrapport 2023-Q2 |
| 2023-04-14 | - | Extra Bolagsstämma 2023 |
| 2023-02-17 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-14 | - | Årsstämma |
| 2023-02-10 | - | X-dag ordinarie utdelning CSMED 0.00 DKK |
| 2022-11-18 | - | Bokslutskommuniké 2022 |
| 2022-08-13 | - | Kvartalsrapport 2022-Q3 |
| 2022-05-20 | - | Kvartalsrapport 2022-Q2 |
| 2022-02-18 | - | Kvartalsrapport 2022-Q1 |
| 2021-12-10 | - | X-dag ordinarie utdelning CSMED 0.00 DKK |
| 2021-12-09 | - | Årsstämma |
| 2021-11-18 | - | Bokslutskommuniké 2021 |
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Spotlight DK |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
2022-03-23 15:05:18
CS MEDICA A/S ("CS MEDICA" or the "Company") announces today that the United States Patent and Trademark Office has approved CS MEDICA's trademark CANNASEN®, registration no. 6,624,142.
The trademark approval of CANNASEN® is an important step in CS MEDICA's market strategy to expand sales of its product line CANNASEN® in the US market. The trademark registration no. for CANNASEN® is 6,624,142 and is valid until November 19, 2028.
"The validation of CANNASEN® being officially confirmed as a trademark in the US is of key importance for our strategy going forward in the North American market." says CEO Lone Henriksen.
For more information about CS MEDICA, please contact:
Lone Henriksen, CEO
Phone: + (45) 71 20 30 47
Email: lh@galaxapharma.com
Website: https://www.cs-medica.com/